Anna Ljung has a master's degree in Economic and Business Administration from Stockholm School of Economics. Anna Ljung has more than 15 years of experience from the pharmaceutical industry. She is currently serving as CEO of Moberg Pharma AB, chairman of the board of OncoZenge AB and board member of Saniona AB. In addition, Anna Ljung has previously been serving as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB. Anna Ljung is independent in relation to the company, its management, and its largest shareholders.

A presentation of the current members of the board of directors is available on ADDvise Group's website.

The nomination committee's full proposals to the AGM 2022 will be published in connection with the notice to the AGM 2022.

The nomination committee of ADDvise Group for the AGM 2022 consists of Per-Anders Tammerlöv (chairman of the nomination committee) appointed by Rikard Akhtarzand, shareholder through direct and indirect ownership, Per Åhlgren, shareholder through indirect ownership, Magnus Vahlquist, shareholder through direct and indirect ownership and Staffan Torstensson, chairman of ADDvise Group AB. The members of the nomination committee jointly represent approximately 36 per cent of the votes in the company.  

For further information, please contact:
Hanna Myhrman, General Counsel
+46 709 - 82 92 23
hanna.myhrman@addvisegroup.se

About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se,is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.